References

  1. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010;21:2028-2035.
  2. Appel GB, Jayne D. Lupus Nephritis. In: Johnson R, Floege J, Feehaly J, eds. Comprehensive Clinical Nephrology, 4th Edition. Philadelphia, Pa. Elsevier, 2010:308-321.
  3. D’Agati V, Appel GB. Lupus Nephritis: Pathology and Pathogenesis. In: Wallace DJ and Hahn BH, eds. Dubois’ Lupus Erythematosus 7th Edition.
    Philadelphia, Pa. Lippincott Williams & Wilkins, 2007:1094-1111.
  4. Appel GB, Radhakrishnan J, D’Agati V. Secondary Glomerular Diseases.  In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, eds. The Kidney. 9th Edition, Philadelphia, Pa. Elsevier, 2011:1192-1202.
  5. Rus V, Maury EE, Hochberg MC. The Epidemiology of Systemic Lupus Erythematosus. In: Wallace DJ and Hahn BH, eds. Dubois’ Lupus Erythematosus 7th Edition. Philadelphia. Lippincott Williams & Wilkins, 2007:34-45.
  6. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204-210.
  7. Appel GB. New and future therapies for lupus nephritis. Cleve Clin J Med 2012;79:134-140.
  8. Clatworthy MR, Smith KGC. Systemic lupus erythematosus: Mechanism. In Mason J, Pusey C, ed. The Kidney in Systemic Autoimmune Disease. Amsterdam, the Netherlands. Elsevier, 2008:285-309.
  9. Tsokos GC. Systemic lupus erythrematosus. N Eng J Med 2011;365:2110-2121.
  10. Weening JJ, D’Agati VD,  Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus nephritis revisited. Kidney Int 2004; 65:521-530.
  11. Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-557.
  12. Illei GG, Austin HA, Crane M, et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-257.
  13. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350: 971-980.
  14. Houssiau FA, Vasconcelos C, D’Cruz D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
  15. Houssiau FA, Vasconcelos C, D’Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-64.
  16. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:968-975.
  17. Chan TM, Li FK, Tang CS, et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162.
  18. Chan TM, Tse KC, Tang CS, Mok MY, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084.
  19. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-2228.
  20. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Amer Soc Nephrol 2009;20:1103-1112.
  21. Walsh M, Solomons N, Jayne D. Mycophenolate mofetil in patients with lupus nephritis and poor renal function: Results from a randomized controlled trial. Data presented at Renal Week 2008. Abstract SA-PO2953.
  22. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-742.
  23. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;36:1886-1895.
  24. Houssiau FA, D’Cruz D Sangles S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis. Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-2089.
  25. Moroni G, Doria A, Mosca M, et al. A randomized, pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-932.
  26. Austin H, Ilei GG, Braun MJ, Balow JE. Randomized controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-911.
  27. Radhakrishnan J, Moutzouris DA, Ginzler E, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-160.